A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study)

CompletedOBSERVATIONAL

Enrollment

142

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions

Early Stage Breast Cancer

Trial Locations (2)

Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston

The Ottawa Hospital Research Institute, Ottawa